Fate Therapeutics Inc (FATE) stock
FATENasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/3016% above fair value
$1.28−0.06 (-4.48%)
Close on Nov 13, 2026Market cap $153.37MP/E –Yield –
Fate Therapeutics price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Fate Therapeutics's price to sales ratio was 28.9× on Nov 11, 2026, against 18.4× a year earlier. Over the last 5 years it ranged from 1.5× to 102.0×, with a median of 19.2×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 28.9× | +13.0 |
| 2025 | Dec 31, 2025 | 15.9× | +1.9 |
| 2024 | Dec 31, 2024 | 14.0× | +10.5 |
| 2023 | Dec 29, 2023 | 3.5× | −10.7 |
| 2022 | Dec 30, 2022 | 14.2× | −87.9 |
| 2021 | Dec 31, 2021 | 102.0× | −329.3 |
| 2020 | Dec 31, 2020 | 431.4× | +276.6 |
| 2019 | Dec 31, 2019 | 154.7× | −46.8 |
| 2018 | Dec 31, 2018 | 201.6× | +139.9 |
| 2017 | Dec 29, 2017 | 61.7× | +42.4 |
| 2016 | Dec 30, 2016 | 19.3× | −125.5 |
| 2014 | Apr 30, 2014 | 144.8× | +139.4 |
| 2013 | Dec 31, 2013 | 5.4× | – |
See a number that looks wrong?